You are here

Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DA036289-01
Agency Tracking Number: R43DA036289
Amount: $279,256.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
WOBURN, MA 01801-
United States
DUNS: 161843057
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (781) 932-4142
Business Contact
Phone: (781) 932-4142
Research Institution

DESCRIPTION (provided by applicant): Chronic pain can result from various disease conditions and about 45% of the U. S. population seeks medical help for treatment of pain. Neuropathic pain is a type of chronic pain which is very difficult to treat, and most patients do not get adequate relief. A promising therapeutic drug target for the treatment of inflammation and pain is the cannabinoid CB2 receptor. In Phase I of this proposal our focus will be on the structural optimization of our lead template to develop a high efficacy CB2 selective agonist with pain suppression potential and with no CNS side effects. Established in vivo and in vitro pharmacological assays will be used to identify compounds that: 1) are highly selective for CB2 over CB1 receptors; 2)possess high efficacy and high potency in binding and activating the CB2 receptor; 3) possess high efficacy in reversing allodynia (i.e., nociceptive behavior in response to normally non-noxious stimuli); and 4) lack cannabimimetic side effects in whole animals that are typically indicative of CB1 receptor activation. The long-term objective of this proposal is to develop a novel drug for treatment of chronic pain which is both safe and effective. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:8. Project Narrative Neuropathic pain is a type of chronic pain which is very difficult to treat since most patients do not get adequate relief with existing medications. The goal of this proposal is to develop CB2 receptor agonists with limited or no CNS side effects for the treatment of chronic pain.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government